A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2 Study to Evaluate the Efficacy and Safety of UI030 in COVID-19 Patients

Korea United Pharm., NCT05055414, NCT05055414, Nov 2022

Budesonide for COVID-19

27th treatment shown to reduce risk in September 2021, now with p = 0.000003 from 15 studies, recognized in 10 countries.

No treatment is 100% effective.
Protocols combine treatments.

Estimated 140 patient budesonide early treatment RCT with results not reported over 4 years after estimated completion.
4 budesonide RCTs have results missing long after expected1-4
The trials report a total of 916 patients, with 1 trial having actual enrollment of 146, and the remainder estimated.
Korea United Pharm. et al., 1 Nov 2022, Double Blind Randomized Controlled Trial, placebo-controlled, South Korea, trial NCT05055414 (history).